AzTrials
AzTrials

Metastatic Castration-resistant Prostate CancerPhase 2NCT01972217

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

A Phase 2 study testing Olaparib, Abiraterone and Prednisone or prednisolone in people with Metastatic Castration-resistant Prostate Cancer, run by AstraZeneca at 41 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once daily. Read more about this study

Who is it for?
Ages 18 to 130 years, men only
What is being tested?
Olaparib, Abiraterone and Prednisone or prednisolone
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
158 participants
Where
41 sitesin 11 countries
Study dates
1 Apr 2014to 24 Aug 2023
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 130 years
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Provision of signed and dated written informed consent prior to any study specific procedures.
  • Male aged 18 years and older.
  • Histologically or cytologically proven diagnosis of prostate cancer.
  • Candidate for abiraterone therapy with documented evidence of metastatic castration-resistant prostate cancer. Metastatic status is defined as at least one documented metastatic lesion on either bone scan or CT/MRI scan. Castration resistant prostate cancer is defined as rising PSA or other signs of disease progression despite treatment with androgen deprivation therapy and the presence of a castrate level of testosterone (≤50 ng/dL).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 with no deterioration over the previous 2 weeks.
  • Patients must have a life expectancy ≥12 weeks.
Show all 10Show fewer
  • Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations, and completing PRO instruments.
  • Patients must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.
  • For the randomised phase only, patients must have received chemotherapy in the form of docetaxel treatment for metastatic castration-resistant prostate cancer. Note: patients who discontinued docetaxel for toxicity reasons and without completing the full course will still be eligible to enter this study provided they received at least 2 cycles of chemotherapy.
  • Provide informed consent for the pharmacogenetic sampling and analyses.

Who cannot join

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents and/or staff at the study site).
  • Previous treatment in the present study.
  • Treatment with any of the following:
  • Previous exposure to any 2nd generation anti-hormonal including abiraterone and enzalutamide
  • More than 2 prior courses of chemotherapy for metastatic prostate cancer
  • Previous use of immunotherapy or radium-223 for the treatment of metastatic prostate cancer
Show all 36Show fewer
  • Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment;
  • Any previous exposure to a CYP17 (17α-hydroxylase/C17,20-lyase) inhibitor;
  • Substrates of CYP2D6 with a narrow therapeutic index (eg, thioridazine);
  • Potent inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort).
  • Any previous treatment with a PARP inhibitor, including olaparib.
  • With the exception of alopecia or toxicities related to the use of gonadotropinreleasing hormone agonists, any unresolved toxicities from prior therapy greater than CTCAE Grade 2 at the time of starting study treatment.
  • Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment.
  • As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
  • Any of the following cardiac criteria:
  • Mean resting QTc >470 msec obtained from 3 ECGs
  • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.
  • Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
  • Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
  • Absolute neutrophil count (ANC) <1.5 x 109/L
  • Platelet count <100 x 109/L
  • Haemoglobin (Hb) <100 g/L
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN) if no demonstrable liver metastases or >5 x ULN in the presence of liver metastases
  • Total bilirubin >1.5 x ULN if no liver metastases or >3 x ULN in the presence of liver metastases (except in the case of Gilbert's disease)
  • Creatinine >1.5 x ULN concurrent with creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5 x ULN
  • If bone metastases are present and liver function is otherwise considered adequate by the Investigator then elevated alkaline phosphatase (ALP) will not exclude the patient.
  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of olaparib or abiraterone.
  • History of hypersensitivity to active or inactive excipients of olaparib or abiraterone or drugs with a similar chemical structure or class to olaparib or abiraterone.
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  • Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, at the Investigator's discretion.
  • Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
  • Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  • Exclusion from the genetic research may be for any of the exclusion criteria specified in the main study or any of the following:
  • Previous allogeneic bone marrow transplant.
  • Non-leukocyte depleted whole blood transfusion within 120 days of the date of the pharmacogenetic sample collection.

Trial locations and contacts

41 sites in 11 countries.

41 sites in 11 countries

Spain7 sites

  • Research Site

    Badalona, 08916

  • Research Site

    Córdoba, 14004

  • Research Site

    Girona, 17007

  • Research Site

    L'Hospitalet de Llobregat, 08908

  • Research Site

    Madrid, 28050

  • Research Site

    Palma de Mallorca, 7014

  • Research Site

    Valencia, 46010

Other trials in Spain

United Kingdom6 sites

  • Research Site

    Cardiff, CF14 2TL

  • Research Site

    Exeter, EX2 5DW

  • Research Site

    Manchester, M20 4BX

  • Research Site

    Plymouth, PL6 8DH

  • Research Site

    Torquay, TQ2 7AA

  • Research Site

    Westcliff-on-Sea, SS0 0RY

Other trials in United Kingdom

Italy5 sites

  • Research Site

    Lecce, 73100

  • Research Site

    Mirano, 30035

  • Research Site

    Naples, 80131

  • Research Site

    Parma, 43100

  • Research Site

    Pisa, 56126

Other trials in Italy

Russia4 sites

  • Research Site

    Ivanovo, 153040

  • Research Site

    Moscow, 115478

  • Research Site

    Moscow, 125284

  • Research Site

    Saint Petersburg, 197022

Other trials in Russia

Belgium3 sites

  • Research Site

    Edegem, 2650

  • Research Site

    Liège, 4000

  • Research Site

    Wilrijk, 2610

Other trials in Belgium

Canada3 sites

  • Research Site

    Greenfield Park, Quebec, J4V 2H1

  • Research Site

    London, Ontario, N6A 4G5

  • Research Site

    Montreal, Quebec, H2L 4M1

Other trials in Canada

Czechia3 sites

  • Research Site

    Brno, 656 53

  • Research Site

    Brno, 656 91

  • Research Site

    Liberec, 460 63

Other trials in Czechia

France3 sites

  • Research Site

    Angers, 49933

  • Research Site

    Dijon, 21079

  • Research Site

    Lyon, 69373

Other trials in France

Netherlands3 sites

  • Research Site

    Arnhem, 6815 AD

  • Research Site

    Maastricht, 6202 AZ

  • Research Site

    Nijmegen, 6532 SZ

Other trials in Netherlands

United States2 sites

  • Research Site

    Lake Success, New York, 11041

  • Research Site

    San Diego, California, 92123

Other trials in United States

Poland2 sites

  • Research Site

    Gdansk, 80-214

  • Research Site

    Warsaw, 02-781

Other trials in Poland

About this study

Official title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel

This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo given in addition to abiraterone. Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg twice daily (bid) will be administered with the abiraterone in this study.

Read the detailed description

This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and PK of olaparib when given in addition to abiraterone 1000 mg once daily. Part B is a randomised, double-blind, placebo-controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo in addition to abiraterone.

Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of patients with metastatic CRPC. Prednisone or prednisolone 5 mg bid will be administered with the abiraterone in this study, but throughout this protocol the treatment will be referred to simply as abiraterone.

For Part A of the study, 15 to 18 evaluable patients (Cohorts 1 and 2) are planned to be enrolled from approximately 4 sites in approximately 1 or 2 countries, and a further 12 patients may be recruited into a 3rd cohort if necessary.

For Part B of the study, approximately 140 patients who have received prior chemotherapy containing docetaxel will be randomised from approximately 40 sites in North America and Europe. Patients who have been dosed in Part A of the study may not participate in Part B.

Being tested
Olaparib, Placebo, Abiraterone, Prednisone or prednisolone
Keywords
Olaparib, castration-resistant, metastatic prostate cancer, Prior Docetaxel Chemotherapy
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OlaparibDrug

    Also called PARP inhibition

    Olaparib bid

  • PlaceboDrug

    Also called Placebo to PARP inhibition

    Placebo bid

  • AbirateroneDrug

    Abiraterone 1000 mg

  • Prednisone or prednisoloneDrug

    Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.

Study groups in NCT01972217
Study groupRoleWhat they receive
OlaparibActive comparator200 mg or 300 mg bid
Receives: Drug: Olaparib; Drug: Abiraterone; Drug: Prednisone or prednisolone
PlaceboPlacebo comparatorplacebo to match olaparib bid
Receives: Drug: Placebo; Drug: Abiraterone; Drug: Prednisone or prednisolone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part A: Percentage of Patients Experiencing Adverse Events (AEs)

    The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.

    Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows:

    Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.

    'c-r' = causally related 'discont' = discontinuation.

    Measured: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.

  2. Part A: Number of Patients With Dose Limiting Toxicities (DLTs)

    DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A.

    A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC.

    A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance.

    Measured: From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.

  3. Part B: Median Radiological Progression-Free Survival (rPFS) Time

    The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death.

    Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.

    Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).

    Measured: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

  4. Part B: Percentage of Patients With Progression Events or Death (rPFS)

    The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death.

    Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.

    Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).

    The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death.

    Measured: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Secondary outcomes (16)

  1. Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  2. Part A PK: Abiraterone Cmax,ss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  3. Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  4. Part A PK: Abiraterone Tmax,ss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  5. Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  6. Part A PK: Abiraterone Cmin,ss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  7. Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

    Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  8. Part A PK: Abiraterone AUCss

    Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.

    Only patients with data available for analysis at each time point are presented.

    Measured: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

  9. Part B: Percentage of Patients Experiencing AEs

    The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.

    Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows:

    Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.

    'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo.

    Measured: From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).

  10. Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels

    The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.

    The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease.

    Measured: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

  11. Part B: Percentage of Patients With PSA Responses

    The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.

    A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline.

    A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline.

    Patients may have had more than 1 single visit response or confirmed response but were counted once.

    Measured: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

  12. Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level

    The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.

    The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease.

    Measured: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

  13. Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])

    The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone.

    The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2.

    CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to <10 millimetres.

    PR: At least a 30% decrease in the sum of diameters of target lesions from baseline.

    The percentage of patients with a response is presented.

    Measured: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

  14. Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)

    The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.

    TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death.

    TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.

    Measured: From randomisation until analysis cut-off date (up to approximately 3 years).

  15. Part B: Median Overall Survival (OS)

    OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.

    OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented.

    Measured: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

  16. Part B: Median Time to Second Progression or Death (PFS2)

    The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression.

    Measured: From randomisation until analysis cut-off date (up to approximately 3 years).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2013 (estimated)
  2. Study start1 Apr 2014
  3. Primary completion22 Sep 2017
  4. Study completion24 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
158 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01972217
Sponsor's protocol ID
D081DC00008
Other IDs
UVA97934, 2013-003520-37
Status last verified
Oct 2023
First submitted
24 Oct 2013
Last updated
14 Nov 2023
Data monitoring committee
No
Individual data sharing
Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Publications

  • Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, Saad F. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4.

    PubMed 29880291

  • Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, Clarke NW. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2022 Oct;23(10):1297-1307. doi: 10.1016/S1470-2045(22)00498-3. Epub 2022 Sep 2.

    PubMed 36063830

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Olaparib, Abiraterone and Prednisone or prednisolone in people with Metastatic Castration-resistant Prostate Cancer, run by AstraZeneca at 41 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 41 sites in Spain, United Kingdom, Italy, Russia, Belgium and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Oct 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part A: Percentage of Patients Experiencing Adverse Events (AEs) (time frame: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01972217, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in